Dr. Barth is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Elm and Carlton St
Buffalo, NY 14263Phone+1 716-845-2333Fax+1 716-845-8003- Is this information wrong?
Summary
- Dr. Matthew Barth is a pediatric hematologist/oncologist in Buffalo, NY and is affiliated with John R Oishei Children's Hospital and Roswell Park Comprehensive Cancer Center. He received his medical degree from SUNY Upstate Medical University and has been in practice 12 years. He is experienced in lymphoma, personalized medicine, leukemia, stem cell transplant, cellular therapy and neuro oncology.
Education & Training
- University at BuffaloFellowship, Pediatric Hematology/Oncology, 2008 - 2011
- University at BuffaloResidency, Pediatrics, 2005 - 2008
- SUNY Upstate Medical UniversityClass of 2005
Certifications & Licensure
- NY State Medical License 2008 - 2025
- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Awards, Honors, & Recognition
- Young Investigator Award International Society of Paediatric Oncology, 2016
- Henry C. and Bertha H. Buswell Fellowship University at Buffalo, 2011-2014
- Travel Award 11th International Conference on Malignant Lymphoma, 2011
- Join now to see all
Clinical Trials
- Treatment for Advanced B-Cell Lymphoma Start of enrollment: 2013 Jan 01
- Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL Start of enrollment: 2015 Aug 21
Publications & Presentations
PubMed
- Univariate and multivariate family-based association analysis of the IL-13 ARG130GLN polymorphism in the Childhood Asthma Management Program.DeMeo DL, Lange C, Silverman EK, Senter JM, Drazen JM, Barth MJ, Laird N, Weiss ST> ;Genetic epidemiology.
- AMG176, an MCL-1 inhibitor, is active in pre-clinical models of aggressive B-cell lymphomas.Pallawi Torka, Tara Russell, Cory Mavis, Juan Gu, Paola Ghione, Matthew Barth, Francisco J Hernandez-Ilizaliturri> ;Leukemia & Lymphoma. 2023 Jun 1
- An institutional review of genomic sequencing in pediatric solid tumors.Turco GM, Gupta A, Monteleone P, Kelly KM, Klein RD, Wiltsie L, Barth M> ;Pediatric blood & cancer. 2023-04-05
- Join now to see all
Abstracts/Posters
- BCL-Xl Expression Is Druggable Biomarker Associated with a Poor Clinical Outcome in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Matthew J. Barth, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Polatuzumab Vedotin, an Antibody-Drug Conjugate Targeting CD79b, Is a Highly Active Agent Against Burkitt Lymphoma and Primary Mediastinal B-Cell LymphomaMatthew J. Barth, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
- NCCN Guidelines Highlight ‘Complicated’ Treatment for Pediatric LymphomasJanuary 14th, 2020
Grant Support
- Scholar AwardSt. Baldrick's Foundation2013–2018
Professional Memberships
- Member
- Member
- American Society of Pediatric Hematology/OncologyMember
- International Society of Paediatric OncologyMember
- Children's Oncology GroupMember
Hospital Affiliations
- John R Oishei Children's HospitalBuffalo, New York
- Roswell Park Comprehensive Cancer CenterBuffalo, New York
- KALEIDA HealthBuffalo, New York
External Links
- Women & Children's Hospital of Buffalohttp://www.wchob.org/ubmdpediatrics
- Roswell Park Cancer Institutehttps://www.roswellpark.org/
- University at Buffalo Department of Pediatricshttp://medicine.buffalo.edu/pediatrics
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: